P/E ratio for Cytosorbents (CTSO)
P/E ratio as of April 2024 (TTM): -1.36
According to Cytosorbents's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.355. At the end of 2022 the company had a P/E ratio of -2.07.
P/E ratio history for Cytosorbents from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.07 | -71.89% |
| 2021 | -7.35 | -80.63% |
| 2020 | -38.0 | 481.61% |
| 2019 | -6.53 | -54.77% |
| 2018 | -14.4 | -33.41% |
| 2017 | -21.7 | 86.85% |
| 2016 | -11.6 | -22.97% |
| 2015 | -15.1 | 72.51% |
| 2014 | -8.73 | 179.25% |
| 2013 | -3.13 | -27.88% |
| 2012 | -4.33 | 8.33% |
| 2011 | -4.00 | 42.86% |
| 2010 | -2.80 | 17.89% |
| 2009 | -2.38 | 375% |
| 2008 | -0.5000 | -59.09% |
| 2007 | -1.22 | -30.27% |
| 2006 | -1.75 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Boston Scientific BSX | 89.3 | -6,687.62% | 🇺🇸 USA |
 Hologic HOLX | 39.0 | -2,978.23% | 🇺🇸 USA |
 Meridian Bioscience VIVO | 35.0 | -2,684.55% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.